Study on the role and signal transduction mechanism of TAE-mediated berberine chemoimmunotherapy in the treatment of Hepatocellular carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055369

Enrollment

Unknown

Registered

2022-01-08

Start date

2021-02-01

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

experimental group:Berberine

control group:Physiological saline

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 80 years, 2. The clinical staging standard of liver cancer was stage C according to the Barcelona staging standard, 3. Child-Pugh class A or B liver disease, 4. Eastern Cooperative Oncology Group(ECOG) score 0 - 2, 5. Imaging evaluation criteria refer to Modified Response Evaluation Criteria In Solid Tumors(mRECIST) criteria, all lesions are multiple, and at least one lesion can be measured.

Exclusion criteria

Exclusion criteria: 1. Patients who underwent surgery, liver tumor radiofrequency ablation, particle implantation, or liver transplantation before or after admission, 2. Patients who have received radiotherapy and systemic chemotherapy, 3. Patients with severe heart, lung, liver and kidney dysfunction, uncontrolled hypertension, diabetes, or pregnancy, 4. Serious medical complications.

Design outcomes

Primary

Measure	Time frame
TAMs Characteristic marker;	—

Countries

China

Contacts

Public ContactLi jinpeng

Shandong Cancer Hospital

Ljpxxx308@126.com+86 13335195362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026